James Weissman joins Dicerna Pharmaceuticals as CBO
This article was originally published in Scrip
Executive Summary
Dicerna Pharmaceuticals, a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in oncology and other disease areas, has appointed James Weissman chief business officer. Mr Weissman joins Dicerna from MannKind Corporation where he was vice-president of business development, and previously held business development and marketing positions at Pfizer.